GW Pharmaceuticals (NASDAQ:GWPH) posted its quarterly earnings data on Sunday. The biopharmaceutical company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.31, Fidelity Earnings reports. GW Pharmaceuticals had a negative return on equity of 7.46% and a negative net margin of 11.05%.
Shares of NASDAQ:GWPH traded down $0.12 during trading on Tuesday, reaching $219.16. 67,773 shares of the stock were exchanged, compared to its average volume of 892,964. The firm’s 50-day moving average price is $217.57 and its 200 day moving average price is $163.58. The firm has a market cap of $6.87 billion, a price-to-earnings ratio of -127.36 and a beta of 2.15. GW Pharmaceuticals has a 12-month low of $87.07 and a 12-month high of $219.57. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.31 and a current ratio of 5.13.
GWPH has been the subject of a number of recent research reports. SVB Leerink downgraded shares of GW Pharmaceuticals from an “outperform” rating to a “market perform” rating and lifted their price target for the stock from $200.00 to $220.00 in a report on Thursday, February 4th. Raymond James reaffirmed a “hold” rating on shares of GW Pharmaceuticals in a research note on Monday, February 22nd. Needham & Company LLC reissued a “hold” rating on shares of GW Pharmaceuticals in a research note on Wednesday, February 3rd. HC Wainwright cut GW Pharmaceuticals from a “buy” rating to a “neutral” rating and raised their price objective for the stock from $162.00 to $220.00 in a report on Thursday, February 4th. Finally, Zacks Investment Research upgraded GW Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, April 27th. Eleven research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $197.75.
About GW Pharmaceuticals
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas. Its lead product is Epidiolex, an oral medicine for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex.
Further Reading: VIX – Volatility Index
Receive News & Ratings for GW Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.